Health Condition 1: null- Non-alcoholic fatty liver disease
Conditions
Interventions
Intervention1: H Pylori Eradication therapy: H Pylori therapy (PPI, amoxicillin, clarithromycin and a nitro-imidazole) for a total of 10 days for eradication of H. pylori
Dietary advice and exercise
Sponsors
Department of Gastroenterology Department of Pharmacology AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either gender with age > 18 years 2. All patients of NAFLD with H. pylori infection 3. Patients agreeing to sign on the written informed consent document
Exclusion criteria
Exclusion criteria: Patients with: 1. Cirrhosis 2. Endoscopy proven peptic/ duodenal ulcer(s) 3. History of any other infectious disease at present requiring pharmacotherapy(eg Tuberculosis) 4. History of intake of any of the agents used in H. pylori eradication therapy within past 3 months 5. Patients on anti-arrhythmic drug/ drug(s) having potential to cause QT prolongation 6. History of allergy to any of the components of H. pylori eradication therapy any time in the past 7. Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in liver fat content measured by transient elastography (FibroScan) with controlled attenuation parameter (CAP)Timepoint: 24 weeks after therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in TNF-alfpha, GSH:GSSG ratio, metabolic markers and anthropometric parametersTimepoint: at 12 and/or 24 weeks | — |
Countries
India
Contacts
Public ContactDr Shalimar
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed